Question 1

What is Beren Therapeutics' adrabetadex, and when will the FDA decide on it?

Accepted Answer

Adrabetadex is Beren's investigational cyclodextrin for infantile-onset Niemann-Pick type C, given into the spinal fluid every 2 weeks in trials. The FDA's goal date is November 17, 2026. What Beren is asking for: approval for NPC whose neurological symptoms begin before age 6. What the application rests on: Beren's comparisons of treated children with untreated patients from records, which it says show longer survival and slower decline. The only randomized trial, in people aged 4 to 21, showed no difference from sham. Where to watch: the adrabetadex FDA decision page and our guide for parents of young children with NPC. Source: Beren Therapeutics, March 12, 2026.

Question 2

Can a child get adrabetadex before the FDA decides?

Accepted Answer

Possibly, through Beren's expanded access program, which Beren says it has run since 2021 and continues during the FDA review. Under FDA rules, an expanded access request comes from the treating doctor, so the first step is the child's neurologist.

No NPC treatment trial recruiting on ClinicalTrials.gov accepted children under 4 as of October 14, 2026.

Source: Beren Therapeutics, June 10, 2026.

Question 3

What is Beren's Test for NPC program?

Accepted Answer

A program Beren started on September 9, 2026 that offers no-cost genome sequencing to eligible families, along with genetic counseling, to find people with NPC who have not been diagnosed. Beren estimates that about two-thirds of Americans with NPC are undiagnosed.

Ask a doctor or genetic counselor to go over any result.

Source: Beren Therapeutics, September 9, 2026.

Question 4

What rare diseases does Beren Therapeutics P.B.C. focus on?

Accepted Answer

Beren Therapeutics P.B.C. has active programs across 1 rare disease: Niemann-Pick Disease Type C. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.

Question 5

How can I find Beren Therapeutics P.B.C. clinical trials for rare diseases?

Accepted Answer

The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Beren Therapeutics P.B.C., pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.

Question 6

How do I enroll in a Beren Therapeutics P.B.C. clinical trial?

Accepted Answer

To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.

Question 7

What FDA-approved rare disease drugs does Beren Therapeutics P.B.C. have?

Accepted Answer

None as of October 2026. Beren Therapeutics P.B.C. has no FDA-approved drug yet; its programs are still in trials.

Most advanced: Adrabetadex (Phase 3).

Where to watch: the FDA calendar lists any Beren Therapeutics P.B.C. application once a decision date is public, and the trials list on this page shows what is recruiting now.

Beren Therapeutics P.B.C.

Active Clinical Trials

FDA-Approved Drugs

Rare Disease Focus Areas (1)

Patient Resources

Frequently Asked Questions About Beren Therapeutics P.B.C.

Active Clinical Trials

FDA-Approved Drugs

Rare Disease Focus Areas (1)

Related Companies

Patient Resources

Frequently Asked Questions About Beren Therapeutics P.B.C.